Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amanda Clarke

Showing results (81-90 of 124) with videos related to

Pageof 13
Sort By:
The International Journal on Drug Policy|February 13, 2017
Poly drug use, chemsex drug use, and associations with sexual risk behaviour in HIV-negative men who have sex with men attending sexual health clinicsJaney Sewell, Ada Miltz, Fiona C Lampe, et al.
HIV Medicine|August 29, 2024
Cardiovascular disease risk in people of African ancestry with HIV in the United KingdomStephanie Ko, Lourdes Dominguez-Dominguez, Zoe Ottaway, et al.
Clinical Pharmacokinetics|December 31, 2015
Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 StudyLaura Dickinson, Janaki Amin, Laura Else, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 5, 2016
Neurocognitive Function and Neuroimaging Markers in Virologically Suppressed HIV-positive Patients Randomized to Ritonavir-boosted Protease Inhibitor Monotherapy or Standard Combination ART: A Cross-sectional Substudy From the PIVOT TrialAlejandro Arenas-Pinto, Wolfgang Stöhr, Hans Rolf Jäger, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 9, 2017
Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed AdultsFrançois Raffi, Chloe Orkin, Amanda Clarke, et al.
Bjpsych Open|May 17, 2017
Clinically significant depressive symptoms and sexual behaviour among men who have sex with menAda R Miltz, Alison J Rodger, Janey Sewell, et al.
Sexually Transmitted Infections|June 15, 2023
Predictors of starting and stopping chemsex in men who have sex with men in England: findings from the AURAH2 prospective studyRobbie Hammond, Valentina Cambiano, Fiona C Lampe, et al.
International Journal of Antimicrobial Agents|July 3, 2017
Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START trialAmit C Achhra, Amanda Mocroft, Michael Ross, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 8, 2018
Brain Perfusion, Regional Volumes, and Cognitive Function in Human Immunodeficiency Virus-positive Patients Treated With Protease Inhibitor MonotherapyLewis J Haddow, Claudia Godi, Magdalena Sokolska, et al.
Kidney International Reports|July 1, 2026
<i>APOL1</i> Variants, AKI, and Progression to Kidney Failure in People of African Ancestry Living with HIVRachel K Y Hung, John W Booth, Rachel Hilton, et al.
Pageof 13

Showing results (81-90 of 124) with videos related to

Sort By:
Pageof 13
The International Journal on Drug Policy|February 13, 2017
Poly drug use, chemsex drug use, and associations with sexual risk behaviour in HIV-negative men who have sex with men attending sexual health clinicsJaney Sewell, Ada Miltz, Fiona C Lampe, et al.
HIV Medicine|August 29, 2024
Cardiovascular disease risk in people of African ancestry with HIV in the United KingdomStephanie Ko, Lourdes Dominguez-Dominguez, Zoe Ottaway, et al.
Clinical Pharmacokinetics|December 31, 2015
Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 StudyLaura Dickinson, Janaki Amin, Laura Else, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 5, 2016
Neurocognitive Function and Neuroimaging Markers in Virologically Suppressed HIV-positive Patients Randomized to Ritonavir-boosted Protease Inhibitor Monotherapy or Standard Combination ART: A Cross-sectional Substudy From the PIVOT TrialAlejandro Arenas-Pinto, Wolfgang Stöhr, Hans Rolf Jäger, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 9, 2017
Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed AdultsFrançois Raffi, Chloe Orkin, Amanda Clarke, et al.
Bjpsych Open|May 17, 2017
Clinically significant depressive symptoms and sexual behaviour among men who have sex with menAda R Miltz, Alison J Rodger, Janey Sewell, et al.
Sexually Transmitted Infections|June 15, 2023
Predictors of starting and stopping chemsex in men who have sex with men in England: findings from the AURAH2 prospective studyRobbie Hammond, Valentina Cambiano, Fiona C Lampe, et al.
International Journal of Antimicrobial Agents|July 3, 2017
Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START trialAmit C Achhra, Amanda Mocroft, Michael Ross, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 8, 2018
Brain Perfusion, Regional Volumes, and Cognitive Function in Human Immunodeficiency Virus-positive Patients Treated With Protease Inhibitor MonotherapyLewis J Haddow, Claudia Godi, Magdalena Sokolska, et al.
Kidney International Reports|July 1, 2026
<i>APOL1</i> Variants, AKI, and Progression to Kidney Failure in People of African Ancestry Living with HIVRachel K Y Hung, John W Booth, Rachel Hilton, et al.
Pageof 13